Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Paris, France – 7 November, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO^® from the ELATIVE trial^1, 2will be presented in two late-breaking sessions, at The Liver Meeting^® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD).